Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants.

Autor:	Shrestha LB; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia., Tungatt K; Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia., Aggarwal A; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Stubis A; Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia., Fewings NL; Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia., Fichter C; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Akerman A; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Rodrigo C; School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia., Tedla N; School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia., Lee S; Research & Education Network, Western Sydney Local Health District, Westmead, NSW, Australia., Lloyd AR; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Brilot F; Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Westmead, NSW, Australia; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia., Britton WJ; Centenary Institute, The University of Sydney, Camperdown, NSW, Australia; RPAH Vaccination Centre, Sydney Local Health District, Sydney, NSW, Australia., Kelleher A; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Caterson ID; RPAH Vaccination Centre, Sydney Local Health District, Sydney, NSW, Australia., Douglas MW; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; Storr Liver Centre, The Westmead Institute for Medical Research, Westmead, NSW, Australia; Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, NSW, Australia., Rockett R; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia., Tangye SG; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia., Triccas JA; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia., Turville SG; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Sandgren KJ; Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia., Bull RA; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia., Cunningham AL; Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. Electronic address: tony.cunningham@sydney.edu.au.
Jazyk:	angličtina
Zdroj:	EBioMedicine [EBioMedicine] 2024 Dec; Vol. 110, pp. 105461. Date of Electronic Publication: 2024 Nov 28.
DOI:	10.1016/j.ebiom.2024.105461
Abstrakt:	Background: Current literature informs us that bivalent vaccines will generate a broader serum neutralizing antibody response to multiple SARS-CoV-2 variants, but studies on how this breadth relates to the memory B cell (MBC) and T cell responses are sparse. This study compared breadth of neutralising antibody, and memory B and T cell responses to monovalent or a bivalent ancestral/Omicron BA.1 COVID-19 booster vaccine. Methods: At baseline and 1-month post-booster, neutralisation activity and frequencies of receptor binding domain (RBD)-specific MBCs and Spike-specific memory T cells were measured against a panel of variants. Findings: Both vaccines boosted neutralising antibodies to 5 variants - Wuhan-Hu-1, Delta, BA.1, BA.5 and JN.1, the latter of which had not yet emerged at the time of sample collection. The bivalent vaccine induced a significantly larger increase in nAb against BA.1 and JN.1. Both vaccines boosted RBD-specific MBC responses to Wuhan-Hu-1, Delta, BA.1 and BA.5 variants with a significantly greater increase for BA.1 in the bivalent group. The breadth of MBCs was significantly higher in those who received the bivalent boost and correlated with nAb breadth. Both vaccines significantly boosted Spike-specific T cell responses to the Wuhan-Hu-1 and BA.5 variants, but only the bivalent vaccine boosted BA.1 responses. Interpretation: These results suggest that the bivalent vaccine confers an advantage against future novel variants due to increased frequency of broadly reactive RBD-specific B cells. Funding: Work supported by NSW Health for the NSW Vaccine, Infection and Immunology Collaborative (VIIM). Competing Interests: Declaration of interests The VIIM Collaborative Group of NSW was funded by NSW Health. A.L.C has received NSW Health grant and performed consultancies for Moderna with honoraria directed to his institution. K.J.S. has received honoraria for talks from Moderna. A.K. has grants from NSW Health, NHMRC, MRFF, NIH, Viiv, Unitaid, DFAT, received consulting fee from Merck and Viiv, travel support from HIN STRIVE investigators meeting, performed leadership and advisory role in Board member Scientia Clinical Research Phase 1 Unit, HIV-NAT Advisory Board ASCOT Trial, Chair of DSMB Aegros Advisory Board and pending patent for siRNA for COVID-19. F.B. has received support from NHMRC, Novartis and MRFF. W.J.B. has received support from NSW Vaccine Accelerator, NHMRC, MRFF and NSW Dust Diseases board. I.D.C. has clinical trials support from Eli Lilly and Boehringer. M.W.D has grants from NHMRC and Gilead Australia, payment from Roche Diagnostics for webinar, GSK travel grant and participated as advisor in Gilead and GSK. R.A.B. and R.R. have NHMRC Investigator grants. S.G.Ta has grants from NHMRC, Job Research Foundation and Allegry and Immunology Foundation of Australasia. S.G.Tu has received grants from MRFF, and New South Wales Health COVID-19 Research Grants Round 2. (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu